Evidence map›Paper›PMID 35417540›Full record

ArticleThe Journal of infectious diseases2022

Functional Compartmentalization of Antibodies in the Central Nervous System During Chronic HIV Infection.

Marianna Spatola, Carolin Loos, Deniz Cizmeci, Nicholas Webb, Matthew J Gorman, Evan Rossignol, Sally Shin, Dansu Yuan, Laura Fontana, Shibani S Mukerji and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Marianna SpatolaRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Carolin LoosRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Deniz CizmeciRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Nicholas WebbRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Matthew J GormanRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Evan RossignolRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Sally ShinRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Dansu YuanRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Laura FontanaRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Shibani S MukerjiMassachusetts General Hospital, Boston, Massachusetts, USA.
Douglas A LauffenburgerMassachusetts Institute of Technology, Cambridge, Massachusetts, USA.
Dana GabuzdaDana Farber Cancer Institute, Boston, Massachusetts, USA.ORCID 0000-0002-4964-5083
Galit AlterRagon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology, and Harvard, Cambridge, Massachusetts, USA.
Ragon Institute of MGH, MIT and Harvard · USDana-Farber Cancer Institute · USMassachusetts General Hospital · USMassachusetts Institute of Technology · US

Funding

COVID Supplement - COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES,75N93019C00052 · NIAID · UNIVERSITY OF GEORGIA · PI ROSS, TED · 2019 to 2025
$74.6M
Technology CoreU19AI135995 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI Laura D. Hughes · 2018 to 2026
$32.0M
The Manhattan HIV Brain BankU24MH100931 · NIMH · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MORGELLO, SUSAN · 2013 to 2023
$14.0M
California NeuroAIDS Tissue NetworkU24MH100928 · NIMH · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ACHIM, CRISTIAN L, MOORE, DAVID J · 2013 to 2023
$13.9M
NATIONAL NEUROLOGICAL AIDS BANKU24MH100929 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SINGER, ELYSE J · 2013 to 2023
$12.5M
Texas NeuroAIDS Research CenterU24MH100930 · NIMH · UNIVERSITY OF TEXAS MED BR GALVESTON · PI GELMAN, BENJAMIN B. · 2013 to 2023
$12.1M
NNTC Data Coordinating CenterU24MH100925 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI FOX, HOWARD S, SHERMAN, SETH · 2013 to 2022
$9.5M
Demystifying the antiviral activity of the IgG3+ antibody responseR37AI080289 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI ALTER, GALIT · 2015 to 2022
$5.8M
Immunologic Signatures of SARS-CoV-2 Vaccination and DiseaseU01CA260476 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI BAROUCH, DAN H. · 2020 to 2024
$3.7M
SARS-CoV-2 Variant TestingR01AI146785 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI LINGWOOD, DANIEL · 2020 to 2024
$3.3M
CHLAMYDIA PNEUMONIAE AND MACROPHAGES IN ATHEROSCLEROSISR01AI042790 · NIAID · UNIVERSITY OF WISCONSIN MADISON · PI BYRNE, GERALD IRWIN · 1999 to 2003
$983k
Immune Activation, Cerebral Metabolic Activity and Depression in Treated HIV-InfectionK23MH115812 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI MUKERJI, SHIBANI SHARON · 2018 to 2022
$926k
Bill & Melinda Gates Foundation INV-001650NCI NIH HHS U01 CA260476NIAID NIH HHS R01 AI042790NIAID NIH HHS R01 AI146785NIAID NIH HHS R37 AI080289NIAID NIH HHS U19 AI135995NIH HHS 3R37AI080289-11S1NIH HHS 75N93019C00052NIMH NIH HHS HHSN271201000030CNIMH NIH HHS HHSN271201000036CNIMH NIH HHS K23 MH115812NIMH NIH HHS R56 MH115853NIMH NIH HHS U24 MH100925NIMH NIH HHS U24 MH100928NIMH NIH HHS U24 MH100929NIMH NIH HHS U24 MH100930NIMH NIH HHS U24 MH100931NINDS NIH HHS U24MH100931
6 · The paper itself

Abstract

The central nervous system (CNS) has emerged as a critical HIV reservoir. Thus, interventions aimed at controlling and eliminating HIV must include CNS-targeted strategies. Given the inaccessibility of the brain, efforts have focused on cerebrospinal fluid (CSF), aimed at defining biomarkers of HIV-disease in the CNS, including HIV-specific antibodies. However, how antibodies traffic between the blood and CNS, and whether specific antibody profiles track with HIV-associated neurocognitive disorders (HAND) remains unclear. Here, we comprehensively profiled HIV-specific antibodies across plasma and CSF from 20 antiretroviral therapy (ART) naive or treated persons with HIV. CSF was populated by IgG1 and IgG3 antibodies, with reduced Fc-effector profiles. While ART improved plasma antibody functional coordination, CSF profiles were unaffected by ART and were unrelated to HAND severity. These data point to a functional sieving of antibodies across the blood-brain barrier, providing previously unappreciated insights for the development of next-generation therapeutics targeting the CNS reservoir.

Indexed as

HIV-1HIV InfectionsCentral Nervous SystemHIV AntibodiesHumansNeurocognitive DisordersHIV Antibodiesantibody functionsARTcerebrospinal fluidcomplement depositionFc receptorsHIV-associated neurocognitive disordersNK activationphagocytosisplasma

Identifiers

PMID35417540
PMCPMC9441210
OpenAlexW4223946145

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.